A men's health brand with a 120,000-subscriber email list launched a compliant TRT program in eight weeks, without hiring a clinical director or negotiating its own pharmacy and lab agreements. Controlled substance credentialing, lab ordering, and pharmacy fulfillment all ran inside FUSE Health infrastructure, with refill cycles tied to lab review cadence. That lab integration removed the manual step that usually breaks TRT retention at refill, and subscription retention came in above DTC health benchmarks.
Core Insights
Introduction
A direct-to-consumer men's health brand with an established email audience of 120,000 subscribers had positioned itself around performance, energy, and body composition. The audience skewed 30 to 55 years old, professional, and with disposable income. TRT demand in the audience was visible and growing — open rates on content touching testosterone and hormone optimization consistently outperformed the brand's benchmark.
The brand had no clinical infrastructure and a strong preference for keeping operations lean. They needed a TRT program that could serve that demand without adding headcount or clinical management overhead.
The Challenge
TRT involves controlled substances in most states, which adds prescribing complexity beyond standard telehealth program categories. The operator needed to confirm that provider credentialing, lab integration, and controlled substance dispensing were all handled within the platform infrastructure before committing to a program design.
The secondary challenge was lab integration. TRT programs require baseline lab work before prescribing. Programs that handle labs manually create friction that breaks subscription retention at the refill stage — the leading cause of poor LTV in TRT programs.
Step 1 — Lab Workflow Integration
Lab orders were integrated into the intake flow before program design was finalized. Patients were prompted to complete required bloodwork as part of the program enrollment process. Results fed directly into the provider review queue without manual routing by the brand's team or the patient.
Step 2 — Controlled Substance Prescribing
Provider credentialing within the FUSE Health network covered the states where the brand's audience was concentrated. Prescribing protocols for testosterone were documented and followed within the async review workflow. Controlled substance prescribing requires more rigorous protocol documentation than standard telehealth categories.
Step 3 — Refill and Lab Cycle Logic
Refill cycles were tied to lab review cadence. Before each refill authorization, patients were prompted to complete updated lab work. The clinical review at refill used updated results to maintain protocol consistency and clinical integrity over long protocol durations.
Integrated Lab Workflow — Lab orders and result reviews were part of the defined workflow. No manual lab coordination was needed at intake or refill.
Controlled Substance Coverage — Provider credentialing covered the primary states in the brand's audience geography. Prescribing protocols documented before the first enrollment.
Refill Retention Through Lab Logic — Refill cycles connected to lab reviews kept patients enrolled rather than dropping at the first manual renewal point.
High LTV Program Category — TRT programs generate some of the highest per-patient LTV in digital health because protocol duration is measured in months or years.
Build Your Telehealth Platform Faster
Launching digital healthcare services requires complex infrastructure. FUSE provides the tools needed to connect patients, providers, and pharmacies in one platform.
Step 4 — Pharmacy Fulfillment
Prescriptions were routed to pharmacy partners configured for controlled substance dispensing. Fulfillment timelines were confirmed before launch so patient expectations were set correctly from the first enrollment. Expectation mismatches on fulfillment timelines are a primary driver of negative reviews in TRT programs.
What Launched
The brand launched a TRT program in eight weeks, which included time to confirm controlled substance credentialing and lab workflow integration. The full workflow from intake through refill ran within FUSE Health infrastructure.
Core Insights
The brand launched a TRT program without hiring a clinical director, negotiating pharmacy agreements, or building lab integration technology. The full workflow from intake through refill ran within FUSE Health infrastructure.
Subscription retention was above benchmarks for DTC health programs because the lab integration reduced the manual friction that typically causes dropout at the refill stage.
References
- FDA GLP-1 announcements (2024–2025)
- Tirzepatide declaratory order (19 Dec 2024)
- Semaglutide declaratory order (21 Feb 2025)
- Drug Shortages Database
- Concerns with Unapproved GLP-1 Drugs for Weight Loss
- Compounding When Drugs Are on the Shortage List
- HHS Telehealth
Daniel is a two-time founder who has scaled service businesses across major U.S. markets. A Y Combinator competition winner, he focuses on removing operational and regulatory barriers so operators can build and scale modern healthcare businesses.
- Background
- Startup Operations & Service Systems
- Experience
- 2x Founder, Multi-Market U.S. Scaling
- Qualifications
- Healthtech Market Expertise & Operational Scaling
- Key Achievement
- Scaled Premier Staff & Eventstaff across major U.S. markets
